A new publication involving amylin, the hormone target of pramlintide, appeared in the journal Headache on October 13, 2026. The study is titled "Plasma amylin levels in migraine and after erenumab treatment: A REFORM study." It was indexed under PubMed ID 42867283. The publication is listed as part of the REFORM study series. No findings, outcomes, or conclusions from the study were provided alongside this listing. This brief reports only that the publication has occurred and the details of its title, journal, and date. Readers interested in pramlintide's approved status and general background can consult the compound overview for further context.
New Publication Links Pramlintide Target Amylin to Migraine Research
See the full pramlintide overview
Source: https://pubmed.ncbi.nlm.nih.gov/42867283/